相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Immunology
Shohei Yamamoto et al.
Summary: A study conducted among healthcare workers in a hospital in Tokyo during the Delta variant epidemic showed that breakthrough infections occurred 2-4 months after vaccination, with all cases being mild or asymptomatic. Despite lower neutralizing antibody titers against the variants compared to the wild-type, there was no difference in antibody levels between breakthrough cases and controls.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
Avishay Spitzer et al.
Summary: A booster dose of BNT162b2 vaccine was associated with a significantly lower risk of SARS-CoV-2 infection among health care workers who were previously vaccinated with a 2-dose series of the same vaccine. The study was conducted in Israel and included 1928 participants with a median follow-up of 39 days.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Medicine, General & Internal
Victoria Hall et al.
Summary: This study investigated the duration and effectiveness of immunity among healthcare workers in the United Kingdom. It found that two doses of the BNT162b2 vaccine provided high short-term protection against SARS-CoV-2 infection, but this protection significantly decreased after six months. However, infection-acquired immunity boosted by vaccination remained high, even more than one year after infection.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Olha Puhach et al.
Summary: The infectious viral load of SARS-CoV-2 Omicron BA.1 is lower than that of Delta in breakthrough infections of vaccinated individuals. Vaccines may lower transmission risk and have a public health benefit.
Article
Immunology
Anastasia Saade et al.
Summary: A study conducted at the University Hospital of Rennes in France found that the incidence of SARS-CoV-2 infection increases over time in fully vaccinated healthcare workers, with age being independently associated with the incidence of infection and vaccination schemes not affecting infection rates.
Article
Multidisciplinary Sciences
Hiam Chemaitelly et al.
Summary: mRNA COVID-19 vaccines provide moderate and short-lived protection against symptomatic Omicron BA.1 and BA.2 infections, but strong and durable protection against COVID-19 hospitalization and death.
NATURE COMMUNICATIONS
(2022)
Review
Virology
Lok Bahadur Shrestha et al.
Summary: The Omicron variant of SARS-CoV-2 is a major public health concern due to its high infectivity and antibody evasion. It has rapidly become the dominant variant worldwide and has evolved through several variants. The evolution of Omicron is thought to be influenced by zoonotic spillage, infection in immunocompromised individuals, and undiagnosed spread in the community. Current research suggests that Omicron is more infectious than the original Wuhan-Hu-1 and Delta variants, but less severe in terms of its impact on lung tissue. Vaccines have shown reduced effectiveness against Omicron, but booster shots can improve efficacy. Broadly neutralizing monoclonal antibodies have limited effectiveness against Omicron, with some exceptions. New variants, such as BA.4 and BA.5, are emerging and are reported to be more transmissible and resistant to immunity generated by previous variants and monoclonal antibodies.
REVIEWS IN MEDICAL VIROLOGY
(2022)
Article
Multidisciplinary Sciences
Steven A. Kemp et al.
Summary: Studies have shown transmission of SARS-CoV-2 among vaccinated healthcare workers, highlighting the need for ongoing infection control measures. The research also introduces a novel approach to identifying transmissions that is scalable and rapid without the need for an infection control infrastructure.
SCIENTIFIC REPORTS
(2022)
Article
Medicine, General & Internal
Matan J. Cohen et al.
Summary: Despite high vaccination rates among health care workers in Israel, a significant number of breakthrough infections were observed during the Omicron wave. A fourth vaccine dose was recommended to mitigate the infection rate. This study found that the fourth dose of the vaccine reduced breakthrough infection rates among hospital staff, although not as much as the third dose.
Article
Medicine, General & Internal
Jostein Starrfelt et al.
Summary: This population-based cohort study evaluated the vaccine effectiveness of different COVID-19 vaccine regimens against SARS-CoV-2 infections, hospitalizations, intensive care admissions, and death. The results showed that the overall adjusted vaccine effectiveness against infection decreased over time, but remained effective against hospitalization. A booster dose significantly increased the effectiveness. Spikevax or a combination of mRNA products provided the highest protection.
Editorial Material
Infectious Diseases
Shui Shan Lee et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Immunology
Loukia Psaridi et al.
Summary: This study aimed to assess the neutralizing antibody immunity against SARS-CoV-2 in healthcare personnel vaccinated with three doses of the BNT162b2 mRNA vaccine. The results showed that the neutralizing antibody levels significantly increased after receiving the booster dose of the vaccine. Younger individuals and those with previous SARS-CoV-2 infection had higher antibody levels, while there was an inverse correlation between antibody levels and comorbidities or tobacco use. At the end of the study period, an increase in neutralizing antibody titers was observed in women.
Review
Environmental Sciences
Jie Deng et al.
Summary: Based on the available data, both homologous and heterologous COVID-19 booster doses have high effectiveness and immunogenicity, with acceptable safety. Heterologous booster doses are more effective than homologous ones, which can help inform public health decisions and reduce vaccine hesitancy.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Article
Infectious Diseases
Sherrie L. Kelly et al.
Summary: According to the model, timely administration of COVID-19 vaccine boosters to eligible individuals, prioritizing the most vulnerable, can reduce infections and hospital admissions. These findings provide evidence-based guidance for decision-makers to plan for administering COVID-19 boosters ahead of winter 2022-2023 to mitigate the health burden and stress on the healthcare system.
INFECTIOUS DISEASES AND THERAPY
(2022)
Article
Immunology
Helena C. Maltezou et al.
Summary: This study assessed the impact of the PfizerBioNTech vaccine on morbidity and absenteeism among healthcare personnel in Greece. The results showed that vaccination significantly reduced morbidity, COVID-19, absenteeism, and duration of absenteeism among healthcare personnel, demonstrating the vaccine's effectiveness in protecting this group and maintaining healthcare services.
Article
Medicine, General & Internal
Yoel Angel et al.
Summary: This cohort study in Tel Aviv, Israel, found that vaccination with the Pfizer-BioNTech BNT162b2 vaccine was significantly associated with a lower incidence of symptomatic and asymptomatic SARS-CoV-2 infection among health care workers more than 7 days after the second dose.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Public, Environmental & Occupational Health
Tamara Pilishvili et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Letter
Medicine, General & Internal
Anoop S. V. Shah et al.
Summary: Vaccination of healthcare workers against SARS-CoV-2 in Scotland was found to reduce household transmission, indicating the positive impact of vaccination on curbing the spread of the virus.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Moriah Bergwerk et al.
Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Helena C. Maltezou et al.
CLINICAL INFECTIOUS DISEASES
(2020)
Editorial Material
Immunology
Helena C. Maltezou et al.
